The inaugural bellwether trial in the multidistrict litigation (MDL) concerning Bard’s implanted port catheters commenced on April 21, 2026, under the supervision of U.S. District Judge David G. Campbell in the District of Arizona. This trial, expected to conclude by May 8, serves as a pivotal test case among the thousands of personal injury lawsuits consolidated in the MDL.
The litigation centers on allegations that Bard’s PowerPort devices, designed for long-term intravenous access, are prone to defects leading to serious complications. Plaintiffs assert that the use of barium sulfate in the catheter material may cause degradation over time, resulting in fractures and migration of the device. Such failures have reportedly led to severe injuries, including infections, blood clots, and, in some cases, death. ([drugwatch.com](https://www.drugwatch.com/news/2026/02/20/what-the-2026-bard-powerport-trials-could-mean-for-patient-safety/?utm_source=openai))
In the current trial, the plaintiff, Robert Cook, contends that his PowerPort device became infected shortly after implantation, necessitating intravenous antibiotic treatment. Cook’s case is one of several selected for early trials intended to gauge jury responses to the evidence and potentially guide future settlement discussions. ([aboutlawsuits.com](https://www.aboutlawsuits.com/bard-powerport-lawsuit/bard-powerport-infection-lawsuit-trial-begin-april-21-2026/?utm_source=openai))
Judge Campbell has scheduled additional bellwether trials to follow throughout 2026 and into early 2027. These trials aim to address various alleged injuries associated with the PowerPort devices, including infections, thrombosis, and fractures. The outcomes of these cases are anticipated to influence the direction of the remaining lawsuits within the MDL. ([aboutlawsuits.com](https://www.aboutlawsuits.com/bard-powerport-lawsuit/six-bard-powerport-lawsuits-before-juries-may-2026-feb-2027/?utm_source=openai))
As the first trial progresses, both legal professionals and affected patients are closely monitoring developments, recognizing the potential implications for patient safety and corporate accountability in the medical device industry.